• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on September 13, 2017September 13, 2023

IgA vasculitis (Henoch Schonlein Purpura)

Need for developing case definitions and guidelines for data collection, analysis, and presentation for IgA vasculitis (Henoch–S...
Read More
Posted on March 13, 2017September 13, 2023

Vasculitic peripheral neuropathy

Need for developing case definition and guidelines for data collection, analysis, and presentation Background to vasculitic perip...
Read More
Posted on September 13, 2016September 14, 2023

Kawasaki disease and immunisation

ADR adverse drug reaction AHA American Heart Association ALTalanine transaminases aspartate transaminase BCG Bacillus Calmette, Gu...
Read More
Posted on August 13, 2016September 14, 2023

Single organ cutaneous vasculitis (SOCV)

AHEI acute hemorrhagic edema of infancy ANCA anti-neutrophil cytoplasmic antibodies BCGB acillus Calmette-Guerin CHCC Chapel Hill...
Read More
Posted on March 13, 2016September 14, 2023

Systemic Lupus Erythematosus

Need for developing case definitions and guidelines for data collection, analysis, and presentation for systemic lupus erythematos...
Read More

Recent Posts

  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024
  • Lessons Learned from Vaccine Safety Surveillance EffortsSeptember 3, 2024
  • Comirnaty COVID-19 mRNA vaccine: standardized template with key considerations for a benefit-risk assessmentAugust 27, 2024
  • Safety by Numbers – August 2024August 14, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy